The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly
heterogeneous patient population and therefore poses unique challenges for therapeutic …

Hepatocellular carcinoma (HCC), the most common primary liver tumor, is notoriously
resistant to systemic therapies, and often recurs even after aggressive local therapies. HCCs …

Objective This trial compared the efficacy and safety of transarterial chemoembolisation
(TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint …

Although transcatheter arterial chemoembolization (TACE) is the standard of care for
intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous disease …

Introduction: Several clinical trials comparing the efficacy and safety of transarterial
chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no …

Transarterial chemoembolization (TACE) is the current standard of treatment for
unresectable intermediate‐stage hepatocellular carcinoma (HCC). Brivanib, a selective dual …

BACKGROUND: In Japan and South Korea, transarterial chemoembolisation (TACE) is an
important locoregional treatment for patients with unresectable hepatocellular carcinoma …

Transarterial chemoembolization (TACE) is considered the gold standard for treating
intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC …

Local-regional treatments play a key role in the management of hepatocellular carcinoma
(HCC). Image-guided tumor ablation is recommended in patients with early-stage HCC …

Hepatocellular carcinoma (HCC) is a common malignancy in developing countries and its
incidence is on the rise in the developing world. The epidemiology of this cancer is unique …